Bayer Aktiengesellschaft (BAYZF)
| Market Cap | 27.90B |
| Revenue (ttm) | 50.34B |
| Net Income (ttm) | -3.52B |
| Shares Out | n/a |
| EPS (ttm) | -3.59 |
| PE Ratio | n/a |
| Forward PE | 5.41 |
| Dividend | 0.13 (0.44%) |
| Ex-Dividend Date | Apr 28, 2025 |
| Volume | 400 |
| Average Volume | 3,578 |
| Open | 28.45 |
| Previous Close | 28.80 |
| Day's Range | 28.29 - 28.45 |
| 52-Week Range | 19.50 - 34.01 |
| Beta | 0.98 |
| RSI | 61.42 |
| Earnings Date | May 13, 2025 |
About Bayer Aktiengesellschaft
Bayer Aktiengesellschaft operates as a life science company worldwide. The company operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment provides prescription products primarily for cardiology and women’s health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy. The Consumer Health segment markets nonprescription over-the-counter medicines, medical products, medicated skin... [Read more]
Financial Performance
In 2024, Bayer Aktiengesellschaft's revenue was 46.61 billion, a decrease of -2.16% compared to the previous year's 47.64 billion. Losses were -2.55 billion, -13.23% less than in 2023.
Financial numbers in EUR Financial StatementsNews
Bayer to Share New Data from KERENDIA® (finerenone) Clinical Trial Program at European Renal Association Congress
WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer today announced that it will present multiple new analyses of the KERENDIA ® (finerenone) clinical trial program at the European Renal Association (ERA) 62nd Con...
Bayer says new lung cancer therapy granted FDA priority review
Bayer wins EU recommendation for label expansion of Regeneron-partnered Eylea
European markets hold steady as traders await fresh cues; Bayer, Philips, SAP on the move
Bayer wins EU watchdog's endorsement for longer Eylea treatment intervals
German drugmaker Bayer on Friday won an endorsement by the European Medicines Agency to extend the intervals between shots of its anti-blindness treatment Eylea, giving it a potential edge over Roche'...
Bayer Launches Centafore Imaging Core Lab to Support Imaging for Clinical Trials and Software as a Medical Device Development
WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer today announced the launch of its Imaging Core Lab Services under the brand name Centafore. With over 25 years of experience supporting more than 200 clinical tr...
Bayer A.G.'s eye disease treatment gets approval in China
Galmed Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update
TEL AVIV, Israel , May 22, 2025 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for cardiometabolic diseases and GI ...
Bayer Highlights New Data from Oncology and Women's Health Portfolios at 2025 ASCO Annual Meeting
WHIPPANY, N.J.--(BUSINESS WIRE)--The latest data from studies across Bayer's oncology and women's health portfolios will be presented at the upcoming 2025 American Society of Clinical Oncology (ASCO) ...
Bayer CEO on managing through the good and bad: Call out the problems
Bayer CEO Bill Anderson takes the stage at the 2025 CNBC CEO Council Summit to talk to leaders about managing through uncertainty and tackling problems head-on.
Dr. Yesmean Wahdan from Bayer Discusses Women's Health Month with YourUpdateTV
May is Women's Health Month – Dr. Yesmean Wahdan Shares Important and Timely Tips to Help Women Prioritize Their Health at Every Life Stage May is Women's Health Month – Dr. Yesmean Wahdan Shares Impo...
Bayer Stock Investment Could Pay Off, But It Is Not For The Faint Of Heart
Bayer seeks Roundup settlement, explores Monsanto bankruptcy, WSJ reports
Bayer is seeking to resolve lawsuits related to its Roundup weedkiller, while exploring a bankruptcy for its Monsanto unit if the settlement plan fails, the Wall Street Journal reported on Thursday, c...
Bayer Seeks New Roundup Settlement While Exploring Monsanto Bankruptcy
Bayer US head says FDA chief reassured pharma executives of timely reviews
Bayer Pharmaceuticals' chief operating officer said the head of the top U.S. drug regulator recently reassured industry executives that the Food and Drug Administration would meet its targets for revi...
Bayer exec: Trump pharma tariffs would negatively impact R&D
Tariffs on pharma products could hinder R&D efforts, says Bayer exec. Read more here
Bayer plunges as Roundup ingredient glyphosate reportedly singled out in RFK's upcoming report
Bayer Profit Drops 35%, Launches Overhaul To Counter Generic Pressure
Bayer AG (OTC: BAYRY) reported on Tuesday that the first quarter of 2025 net profit was 1.3 billion euros (around $1.45 billion), down from 2 billion euros a year ago. The company reported: Adjusted ...
Bayer Profit Drops 35%, Launches Overhaul To Counter Generic Pressure
Bayer AG BAYRY reported on Tuesday that the first quarter of 2025 net profit was 1.3 billion euros (around $1.45 billion), down from 2 billion euros a year ago.
Bayer A.G. (BAYZF) Q1 2025 Earnings Call Transcript
Bayer A.G. (OTCPK:BAYZF) Q1 2025 Earnings Conference Call May 13, 2025 8:00 AM ETCompany ParticipantsBill Anderson - Chairman & CEOWolfgang Nickl -...
Bayer: U.S. Supreme Court could decide in June whether it will hear glyphosate case
Bayer said on Tuesday that the U.S. Supreme Court could decide as early as next month whether it will hear the German company's request to sharply limit litigation that could run into the billions of ...
Bayer earnings drop by a third as woes force first German factory closure in 161 years
Net profit falls to €1.3bn as litigation costs and slowing sales weigh on conglomerate
Bayer shares soar as company records strong cancer drug demand
Bayer’s strong first quarter performance was mainly driven by its pharmaceuticals division, even as its crop-science branch lagged.
Bayer Shares Jump After Results Beat Expectations on Pharma Strength
Bayer posts smaller than expected 7.4% drop in quarterly adjusted profit
Bayer on Tuesday posted a slower decline in first-quarter adjusted earnings than the market had feared as strong prescription numbers for new drugs offset a drop in its soy and cotton seed business.